Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Klareskog, L.; van der Heijde, D.; de Jager, J. P.et al.
[en] Background Etanercept and methotrexate are effective in the treatment of rheumatoid arthritis but no data exist on concurrent initiation or use of the combination compared with either drug alone. We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis. Methods In a double-blind, randomised, clinical efficacy, safety, and radiographic study, 686 patients with active rheumatoid arthritis were randomly allocated to treatment with etanercept 25 mg (subcutaneously twice a week), oral methotrexate (up to 20 mg every week), or the combination. Clinical response was assessed by criteria of the American College of Rheumatology (ACR). The primary efficacy endpoint was the numeric index of the ACR response (ACR-N) area under the curve (AUC) over the first 24 weeks. The primary radiographic endpoint was change from baseline to week 52 in total joint damage and was assessed with the modified Sharp score. Analysis was by intention to treat. Findings Four patients did not receive any drug; thus 682 were studied. ACR-N AUC at 24 weeks was greater for the combination group compared with etanercept alone and methotrexate alone (18.3% years [95% CI 17.1-19.6] vs 14.7%-years [13.5-16.0], p<0.0001, and 12.2%-years [11.0-13.4], p<0.0001; respectively). The mean difference in ACR-N AUC between combination and methotrexate alone was 6.1 (95% CI 4.5-7.8, p<0.0001) and between etanercept and methotrexate was 2.5 (0.8-4.2, p=0.0034). The combination was more efficacious than methotrexate or etanercept alone in retardation of joint damage (mean total Sharp score -0.54 [95% CI -1.00 to -0.07] vs 2.80 [1.08 to 4.51], p<0.0001, and 0.52 [-0.10 to 1.15], p=0.0006; respectively). The mean difference in total Sharp score between combination and methotrexate alone was -3.34 (95% CI -4.86 to -1.81, p<0.0001) and between etanercept and methotrexate was -2.27 (-3.81 to -0.74, p=0.0469). The number of patients reporting infections or adverse events was similar in all groups. Interpretation The combination of etanercept and methotrexate was significantly better in reduction of disease activity, improvement of functional disability, and retardation of radiographic progression compared with methotrexate or etanercept alone. These findings bring us closer to achievement of remission and repair of structural damage in rheumatoid arthritis.
Disciplines :
Rheumatology General & internal medicine
Author, co-author :
Klareskog, L.
van der Heijde, D.
de Jager, J. P.
Gough, A.
Kalden, J.
Malaise, Michel ; Université de Liège - ULiège > Département des sciences cliniques > Rhumatologie
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Silman AJ, Hochberg MC. Epidemiology of the rheumatic diseases. New York: Oxford University Press, 1993.
Drossaers-Bakker K.W., de Buck M., van Zeben D., Zwinderman A.H., Breedveld F.C., Hazes J.M. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 42:1999;1854-1860.
Eberhardt K.B., Fex E. Functional impairment and disability in early rheumatoid arthritis: development over 5 years. J Rheumatol. 22:1995;1037-1042.
Pincus T., Sokka T., Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum. 44:2001;1234-1236.
Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002), Ann Rheum Dis 2002; 61 (suppl 2): ii2-7.
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002; 46: 328-46.
Brennan F.M., Chantry D., Jackson A., Maini R., Feldmann M. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 2:1989;244-247.
Arend W.P., Dayer J.M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum. 38:1995;151-160.
Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 344:2001;907-916.
Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 343:2000;1594-1602.
Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48:2003;35-45.
Bathon J.M., Martin R.W., Fleischmann R.M., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 343:2000;1586-1593.
Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etanercept therapy in rheumatoid arthritis:a randomized, controlled trial. Ann Intern Med. 130:1999;478-486.
Weinblatt M.E., Kremer J.M., Bankhurst A.D., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 340:1999;253-259.
Mohler K.M., Torrance D.S., Smith C.A., et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 151:1993;1548-1561.
Felson D.T., Anderson J.J., Boers M., et al. American College of Rheumatology:preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38:1995;727-735.
van der Heijde D.M., van 't Hof M., van Riel P.L., van de Putte L.B. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 20:1993;579-581.
van Riel P.L., van Gestel A.M. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis. 59:(suppl 1):2000;28-31.
van der Heijde D.M., van Riel P.L., Nuver-Zwart I.H., Gribnau F.W., van de Putte L.B. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1:1989;1036-1038.
Lassere M., Boers M., van der Heijde D., et al. Smallest detectable difference in radiological progression. J Rheumatol. 26:1999;731-739.
Hochberg M.C. A sharper Bonferroni procedure for multiple test of significance. Biometrika. 75:1988;800-802.
van der Heijde D., Simon L., Smolen J., et al. How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 47:2002;215-218.
Weinblatt M.E. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol. 34:1995;43-48.
Weinblatt M.E. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology. 38:1999;19-23.
van Vollenhoven R., Ernestam S., Harju A., Bratt J., Klareskog L. Etanercept versus etanercept plus methotrexate: a registry based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther. 5:2003;R347-R351.
Felson D.T., Anderson J.J., Lange M.L., Wells G., LaValley M.P. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum. 41:1998;1564-1570.
Fries J.F., Spitz P.W., Young D.Y. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol. 9:1982;789-793.
Rau R., Herborn G. Healing phenomena of erosive changes in rheumatoid arthritis patients undergoing disease-modifying antirheumatic drug therapy. Arthritis Rheum. 39:1996;162-168.
Rau R., Wassenberg S., Herborn G., Perschel W.T., Freitag G. Identification of radiologic healing phenomena in patients with rheumatoid arthritis. J Rheumatol. 28:2001;2608-2615.
Sharp J.T., van der Heijde D., Boers M., et al. Repair of erosions in rheumatoid arthritis does occur: results from two studies by the OMERACT subcommittee on healing of erosions. J Rheumatol. 30:2003;1102-1107.
Moreland L.W., Cohen S.B., Baumgartner S.W., et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. J Rheumatol. 28:2001;1238-1244.